AC Immune SA (ACIU) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed AC Immune SA (ACIU) over the past year, gaining 47.9% versus a loss of 28.2%. Over five years, GLSI leads with a -56.5% price change compared with -59.5% for ACIU. AC Immune SA is the larger company by market cap ($248.6 million vs $242.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | GLSI |
|---|---|---|
| Share price | $2.50 | $16.53 |
| Market cap | $248.57M | $242.63M |
| 1-day change | -1.96% | +9.18% |
| YTD return | -20.38% | -21.32% |
| 1-year return | -28.16% | +47.85% |
| 5-year return | -59.55% | -56.45% |
| Forward P/E | 4.20 | — |
| EPS (TTM) | $-0.54 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $34.10 |
| 52-week low | $2.10 | $7.78 |
| Distance from 52-week high | -37.50% | -51.52% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +240.80% | +244.83% |
| Average volume | 201.86K | 140.09K |
| Shares outstanding | 99.43M | 14.68M |
| Employees | 90 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed ACIU by 76.0 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
ACIU vs GLSI FAQ
Which is bigger, AC Immune SA or Greenwich LifeSciences?
AC Immune SA (ACIU) is larger, with a market capitalization of $248.57M compared with $242.63M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, ACIU or GLSI?
GLSI returned +47.85% over the past 12 months, compared with -28.16% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.